Peptide Therapy in Austin, TX Austin Plastic Surgeon Dr. Chuma Major peptide regulatory news this week. The FDA announced on April 15 that it will remove 12 peptides from Category 2 of the 503A bulk drug substances list after seven calendar days. FDA Proposes Exclusion of Semaglutide, Tirzepatide, Liraglutide from 503B Bulks List FDA posted on the topic LinkedIn When will the FDA reclassify BPC 157 to Category 1 Octagon AI